RUNX2 Antibody

Code CSB-PA14439A0Rb
Size US$166
Order now
Image
  • Western Blot
    Positive WB detected in: Hela whole cell lysate, MCF-7 whole cell lysate
    All lanes: RUNX2 antibody at 3μg/ml
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 57, 56, 55 kDa
    Observed band size: 57 kDa

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) RUNX2 Polyclonal antibody
Uniprot No.
Target Names
RUNX2
Alternative Names
Acute myeloid leukemia 3 protein antibody; Alpha subunit 1 antibody; AML3 antibody; CBF alpha 1 antibody; CBF-alpha-1 antibody; CBFA1 antibody; CCD antibody; CCD1 antibody; Cleidocranial dysplasia 1 antibody; Core binding factor antibody; Core binding factor runt domain alpha subunit 1 antibody; Core binding factor subunit alpha 1 antibody; Core-binding factor subunit alpha-1 antibody; MGC120022 antibody; MGC120023 antibody; Oncogene AML 3 antibody; Oncogene AML-3 antibody; OSF 2 antibody; OSF-2 antibody; OSF2 antibody; Osteoblast specific transcription factor 2 antibody; Osteoblast-specific transcription factor 2 antibody; OTTHUMP00000016533 antibody; PEA2 alpha A antibody; PEA2-alpha A antibody; PEA2aA antibody; PEBP2 alpha A antibody; PEBP2-alpha A antibody; PEBP2A1 antibody; PEBP2A2 antibody; PEBP2aA antibody; PEBP2aA1 antibody; Polyomavirus enhancer binding protein 2 alpha A subunit antibody; Polyomavirus enhancer-binding protein 2 alpha A subunit antibody; Runt domain antibody; Runt related transcription factor 2 antibody; Runt-related transcription factor 2 antibody; RUNX2 antibody; RUNX2_HUMAN antibody; SL3 3 enhancer factor 1 alpha A subunit antibody; SL3-3 enhancer factor 1 alpha A subunit antibody; SL3/AKV core binding factor alpha A subunit antibody; SL3/AKV core-binding factor alpha A subunit antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Runt-related transcription factor 2 protein (219-404AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The RUNX2 Antibody (Product code: CSB-PA14439A0Rb) is Non-conjugated. For RUNX2 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA14439B0Rb RUNX2 Antibody, HRP conjugated ELISA
FITC CSB-PA14439C0Rb RUNX2 Antibody, FITC conjugated
Biotin CSB-PA14439D0Rb RUNX2 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA, WB
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE). Inhibits KAT6B-dependent transcriptional activation.
Gene References into Functions
  1. these data indicated that miR-23b was involved in TNF-alpha-mediated reduction of bone marrow mesenchymal stem cell osteogenesis by targeting runx2. PMID: 29234953
  2. that cross-talk between cAMP/PKA signaling and RUNX2 promotes a malignant phenotype of glioma cells PMID: 30203400
  3. Study identified RUNX2 to be targeted by miR-217 which directly bound to RUNX2 mRNA and inhibited its expression in bladder cancer cells. Also, findings demonstrated that RUNX2 expression was upregulated by hsa_circ_0000144. Moreover, rescue assays demonstrated that RUNX2 was a downstream effector molecule of hsa_circ_0000144/miR-217 network. These results revealed the oncogenic role of RUNX2 in bladder neoplasm. PMID: 30098434
  4. In summary, these results reveal that PTHLH expression is a poor prognosis marker in head and neck squamous cell carcinoma patients, and RUNX2-PTHLH axis contributes to head and neck squamous cell carcinoma tumor growth. PMID: 28120940
  5. Knockdown of RUNX2 significantly inhibited TE-1 and EC-109 cell viability, repressed TE-1 cell migration and invasion, and increased TE-1 cell apoptosis and were associated with the activation of the PI3K/AKT and ERK pathways. PMID: 30138923
  6. Results show that RUNX2 gene silencing increased gemcitabine (GEM) sensitivity of p53mutated pancreatic cancer (PaCa) MiaPaCa2 spheres suggesting that RUNX2 is involved in PaCa-GEM resistance in presence of mutated p53. PMID: 29620279
  7. Runx2 overexpression effectively decreased TNF-alpha-induced Bax and cleaved caspase-3 expression levels PMID: 29129496
  8. RUNX2 is one of the promising molecular targets for the treatment of the patients with pancreatic cancer regardless of their p53 status[review] PMID: 29558908
  9. we identified a novel missense mutation of RUNX2 in 2 patients by Whole exome sequencing and showed potential correlations between facial phenotypes and missense mutations in Runt domain through a mini-meta analysis. PMID: 30095610
  10. Mutant Runx2 regulates amelogenesis and osteogenesis through a miR-185-5p-Dlx2 axis. PMID: 29242628
  11. Results show that RUNX2 is highly expressed in bladder cancer tissues and are negatively correlated with miR-154 levels. This is likely through miR-154 binding the 3'-UTR of RUNX2 mRNA, promoting its degradation. PMID: 29048677
  12. Results identified a novel mutation besides the previously known in one patient with cleidocranial dysplasia (CCD). G462X mutation in exon 8 is located in the C-terminus of proline/serine/threonine-rich (PST) domain. It might reduce the Runx2 transacting activity, lower the protein stability, downgrade the expression of bone marker genes, and eventually diminish osteoblast differentiation in CCD patients. PMID: 28703881
  13. Findings reveal a novel mechanism that Runx2 is transcriptionally regulated by HSP90 via the AKT/GSK-3beta/beta-catenin signaling pathway, and by which leads to apoptosis of osteosarcoma cells. PMID: 28681940
  14. Study identifies a novel missense mutation (c.895 T>C, Y299H) in exon 5 of Runx2 gene in patients with cleidocranial dysplasia (CCD). This mutation results in an amino acid change at codon 895 (P.Tyr 299 His.) from a tryptophan codon (TAT) to a histidine codon (CAT). PMID: 29058294
  15. miR-539 functions as a tumor suppressor in colorectal cance, at least in part, by targeting RUNX2. PMID: 28938522
  16. These results indicate activation of DLX5 and RUNX2 via its distal promoter represents a unique feature of GFs, and is important for ECM regulation. Down-regulation of these transcription factors in PAFs could be associated with their property to degrade collagen, which may impact on the process of periodontitis. PMID: 27645561
  17. down-regulated miR-143-5p promotes the differentiation of DPSCs into odontoblasts by enhancing Runx2 expression via the OPG/RANKL signaling pathway. PMID: 28608628
  18. Three novel mutations (R193G, 258fs, Y400X) in cleidocranial dysplasia. PMID: 28505335
  19. The Runx2 is one of the genes responsible for the pathogenesis of osteoarthritis (OA) because RUNX2 is up-regulated in chondrocytes in OA cartilage and a germline haplodeficiency or deletion of Runx2 in articular chondrocytes decelerates OA progression. PMID: 29356961
  20. application of dexamethasone reduced the expression of RUNX2 and beta-catenin in human gingiva-derived mesenchymal stem cells PMID: 28459354
  21. Runt-related transcription factor 2 (RUNX2) was directly negatively regulated by miR-203. PMID: 28525948
  22. prolactin induction of VEGF-C and Runx2 was inhibited partly by Carboxypeptidase-D inhibitors, implicating nitric oxide , produced by PRL-regulated Carboxypeptidase-D, in breast cancer progression PMID: 28364216
  23. This is the novel report describing to demonstrate that the Runx2 expression of MSC is synergistically influenced by the hydrogels elasticity and their manner of ephrinB2 immobilized. PMID: 28300720
  24. Osterix and RUNX2 are transcriptional regulators of sclerostin in human bone PMID: 27154028
  25. High RUNX2 expression is associated with invasive and metastatic potentials of gastric cancer. PMID: 27007162
  26. These findings suggest possible involvement of RUNX2-rs194328 in the etiology of NS-CL+/-P in Korean cleft-parent trios without excess parental transmission. PMID: 23909516
  27. WWOX expression was strongly inhibited in human lung cancers and lung cancer cell lines. Reintroducing WWOX into lung cancer cells inhibited their invasive phenotype through downregulating RUNX2 and its target genes including MMP-9 expression. PMID: 27834355
  28. our results strongly suggest that RUNX2 might be a key player in receptor tyrosine kinase (RTK)-based autocrine loops and a mediator of resistance to BRAF V600E inhibitors involving RTK up regulation in melanoma. PMID: 27102439
  29. Thus, WNT/beta-catenin activation is required for RUNX2 expression in at least some osteosarcoma cell types, where RUNX2 is known to promote expression of metastasis related genes. PMID: 28370561
  30. miR-105/Runx2 axis mediates FGF2-induced ADAMTS expression in osteoarthritis cartilage. PMID: 26816250
  31. regulation of gal-3 expression was strongly correlated with runx2 transcription factor in human thyroid carcinoma. PMID: 28390192
  32. Studied association of runt-related transcription factor 2 (RUNX2) polymorphisms with susceptibility and prognosis of ossification of posterior longitudinal ligament. PMID: 27704615
  33. these studies define a novel fibrinogen-alpha9beta1-SMAD1/5/8-RUNX2 signaling axis can efficiently induce osteogenic differentiation from human embryonic stem cells and induced pluripotent stem cells. PMID: 27331788
  34. Data show that BRD4 controls RUNX2 by binding to the enhancers (ENHs) and each RUNX2 ENH is potentially controlled by a distinct set of TFs and c-JUN as the principal pivot of this regulatory platform. PMID: 28981843
  35. TGF-beta1 stimulates the phosphorylation of Runx2 at three serine amino acids, and this event is required for MMP-13 expression in osteoblastic cells. PMID: 28419442
  36. TP(thymidine phosphorylase ) curbed the expression of three proteins-IRF8, RUNX2, and osterix. This downregulation was epigenetically driven: High levels of 2DDR, a product of TP secreted by myeloma cells, activated PI3K/AKT signaling and increased the methyltransferase DNMT3A's expression PMID: 27658717
  37. Overexpression of miR-196b suppressed cell viability, migration, invasion, and induced apoptosis as well as inhibited TGF-beta induced epithelial mesenchymal transition process in A549 cells. In addition, Runx2 was a putative target of miR-196b, and Runx2 silence remarkably increased cell apoptosis and abolished the promotive effects of miR-196b suppression on cell viability, migration and invasion. PMID: 28950255
  38. Runx2 promotes autophagy in metastatic breast cancer cells by increasing acetylation of alpha-tubulin sub-units of microtubules. PMID: 28345763
  39. Mutation in the RUNX2 gene is associated with acute myeloid leukemia patients with lympho-myeloid clonal hematopoiesis. PMID: 27881874
  40. present observations strongly suggest that RUNX2/mutant p53/TAp63-regulatory axis is one of the key determinants of SAHA sensitivity of p53-mutated pancreatic cancer cells PMID: 28671946
  41. All the three novel RUNX2 mutations significantly reduced the transactivation activity of RUNX2 on osteocalcin promoter. PMID: 28738062
  42. Taken together, these results identify a crucial role for the RUNX cluster in the maintenance and progression of cancer cells and suggest that modulation of the RUNX cluster using the PI polyamide gene-switch technology is a potential strategy to control malignancies. PMID: 28530640
  43. miR-466-mediated attenuation of RUNX2 as a novel therapeutic approach to regulate prostate cancer growth, particularly metastasis to bone. PMID: 28125091
  44. miR-203 has a crucial role in suppressing heterotopic ossification by directly targeting Runx2. PMID: 27787524
  45. mechanical load upregulates expression of Runx2 gene via potentiation of PC1-JAK2/STAT3 signaling axis, culminating to possibly control osteoblastic differentiation and ultimately bone formation. PMID: 27699453
  46. the Runx2 knockdown cells displayed activation of AMP-activated protein kinase (AMPKalpha), the sensor of cellular metabolism. Importantly, the Runx2 knockdown in bone-derived cells resulted in increased sensitivity to both Erk1/2 inhibition and AMPKalpha activation by PD184161 and metformin, respectively, despite increased IGF-1Rbeta and AMPKalpha levels. PMID: 26804175
  47. RUNX2 mutation disturbs the modulatory effects of dental follicle cells and periodontal ligament cells on the differentiation of osteoclasts and osteoblasts, thereby interfering with bone remodelling. These effects may contribute in part to the pathological manifestations of retention of primary teeth and delayed eruption of permanent teeth in patients with cleidocranial dysplasia. PMID: 27509906
  48. RUNX2/P57 gene expression is strongly activated, in a process that is accompanied by enrichment of activating histone marks (H3K4me3, H3ac, and H3K27ac) at the P1 promoter region, to control osteogenic lineage commitment of umbilical cord derived mesenchymal stem cells. PMID: 27689934
  49. provide evidence to show that CBX4 may serve as a tumor suppressor in colorectal carcinoma by recruiting HDAC3 to the Runx2 promoter to impede Runx2 expression PMID: 27864346
  50. Suggest an adhesion-dependent mechanism of RUNX2 for the osteotropism and bone colonization of breast cancer cells and implicate RUNX2 and integrin alpha5 as potential molecular markers for the prediction of bone metastasis. PMID: 27317874

Show More

Hide All

Involvement in disease
Cleidocranial dysplasia (CLCD); Metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly (MDMHB)
Subcellular Location
Nucleus.
Tissue Specificity
Specifically expressed in osteoblasts.
Database Links

HGNC: 10472

OMIM: 119600

KEGG: hsa:860

STRING: 9606.ENSP00000360493

UniGene: Hs.535845

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*